BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 09, 2005
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 5/6 cls
Actelion (SWX:ATLN) Goldman Sachs Stephen McGarry Other Market outperform 2% CHF130.2
Nomura Sam Fazeli Upgrade Neutral (from reduce)
McGarry raised his FY05 and FY06 EPS estimates to CHF4.83 and CHF5.80 from CHF3.83 and CHF5.23. He also increased his FY05 revenue estimate to CHF606.2M ($513.1M) from CHF596.2M ($504.7M) to reflect his increased sales estimate for Tracleer. He now expects the pulmonary arterial hypertension drug to post FY05 sales of CHF587M ($496.8M), up from his previous estimate of CHF577M.
Fazeli raised his rating to "neutral" from "reduce" after ATLN late last month reported 1Q05 sales of CHF146.4M ($122.7M), which was 11% higher than his estimate of CHF132.1M. The increase was driven by Tracleer sales, which were CHF139.8M ($117M) versus Fazeli's estimate of CHF125.1M ($104.7M).
Axcan (TSE:AXP; AXCA) Dundee David Martin...

Read the full 834 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >